^(131)Ⅰ治疗Graves病前后TT_3、TT_4差值和比值变化及预后预测的价值  

Changes of the difference and the ratio of TT_3 TT_4 and their worth for predieting the prognosis in patients with Graves disease before and after therapy by ^(131)Ⅰ

作　　者：王翔[1] 熊淑媛[1] 张新英[1] 梁明[1] 

机构地区：[1]遵义医学院附院核医学科

出　　处：《遵义医学院学报》1995年第1期27-30,共4页Journal of Zunyi Medical University

摘　　要：本文分析187例经131I治疗的Graves病患者血清TT3、TT4变化值，结果表明TT3差值和比值、TT4差值和比值都能够反映131I治疗后甲状腺所受电离辐射破坏的程度，表现为131I治疗后未愈组、甲低级和治愈组的差值、比值间差异有统计学意义（p＜0．001）。并寻找出预测131I治疗未愈或甲低的判断标准，其判断预后的特异度分别为94．6％和94．8％、准确率为89．3％和93．1％、灵敏度为85．8％和84．4％，从而提示用此标准能够在131I治疗3～6个月作出预后的预测。This article analysed the changes of serum TT3 TT4 in 187 patients with Graves disease after treatment with 131 I. The results showed that the difference and the ratio of TT3 TT4 could reflect the damaged level of thyrold gland suffered from the ionizing radiation after treatment by 131 I. There were signifficantly differences in the difference and the ratio TT3 TT4 among the no cure group, hypothyroidism group and cure group (P<0. 001). We found a set of standards for predicting the prognosis of these standards (no cure or hypothyroidism) after 131 I therapy, their predicting specificity was 94. 6% and 94. 8%, accuracy was 89. 3% and 93.1 %, sencitivity was 85. 8% and 84. 4% respectively. It was indicated that these standards can be used to predict the prognosis in three to six month after using 131 I therapy.

关 键 词：GRAVES病 突眼性甲状腺肿 TT3 TT4 预后 

分 类 号：R581.105[医药卫生—内分泌]